Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

M Noshela Ghazanfar, S F Thomsen

Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

OriginalsprogEngelsk
TidsskriftEuropean Annals of Allergy and Clinical Immunology
Vol/bind49
Udgave nummer6
Sider (fra-til)284-285
Antal sider2
ISSN1764-1489
DOI
StatusUdgivet - nov. 2017

ID: 189622756